Reirradiation of Breast Cancer In-Field Recurrences with Curative Intent: Locoregional Practice Patterns, Toxicity, and Survival Outcomes
Source abstract
Abstract
The growing number of breast cancer survivors is expected to increase the absolute number of locoregional recurrences requiring management, necessitating improvements in treating recurrences or tumours that occur within the initial radiation field (IFR). However, there are no guidelines on reirradiation (RT2) for breast cancer IFRs. We aimed to investigate locoregional practice patterns and outcomes. We retrospectively identified patients who received adjuvant RT1 for resected breast cancer and subsequently received curative-intent RT2 for IFRs at two large tertiary centres. A chart review obtained treatment, patient, and tumour characteristics. Descriptive statistics were calculated to characterize practice patterns, toxicity, and survival outcomes. Thirty-five patients met inclusion criteria across 18 years, with mean follow-up time of 43 months. Median time from RT1 to progression was 70.1 months. Most IFRs were in the breast or chest wall alone (48.6%). Regional nodal irradiation (RNI) was given in 23% of RT1 and 48.6% of RT2. Complete field overlap occurred in 60% of patients. Ten patients (28.6%) had a second recurrence (i.e., after RT2). Five-year OS was 65.4%, the median OS was not reached, and the mean OS was 73.7 months (95% CI 59.8–87.7 months). Freedom from recurrence (after RT2) was 71%. Shorter time to initial recurrence was associated with second recurrence (p = 0.018), and second recurrence was found to be predictive of death (p < 0.001). Four (11.4%) patients developed fibrosis, 75% of which developed after RT1. Eight (22.9%) patients developed lymphedema, 75% of which developed after RT1, all of which were documented as stable after RT2. Managing breast cancer IFRs with RT2 appears to be a feasible approach with reasonably consistent practice patterns in appropriately selected patients. Toxicity appears to be driven by the initial treatment course, and survival outcomes are acceptable.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Breast Cancer Treatment Studies · Lymphatic System and Diseases · Effects of Radiation Exposure
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada
Department of Radiation Oncology, Arthur J.E. Child Comprehensive Cancer Center, Calgary, AB T2N 5G2, Canada
Department of Oncology, University of Alberta, Edmonton, AB T6G 2R3, Canada
Department of Medical Physics, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada
Department of Medical Physics, Arthur J.E. Child Comprehensive Cancer Center, Calgary, AB T2N 5G2, Canada
Department of Radiation Oncology, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada
References (25)
Show source-provided references
1. Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy10.1093/jnci/djn233 ↗
2. Local recurrence after mastectomy or breast-conserving surgery and radiation
3. Radiation Therapy for Locally Recurrent Breast Cancer10.1155/2012/571946 ↗
4. Hazard of Recurrence among Women after Primary Breast Cancer Treatment—A 10-Year Follow-up Using Data from SEER-Medicare10.1158/1055-9965.EPI-11-1089 ↗
5. EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale, P., Taylor, C., Correa, C., Cutter, D., Duane, F., Ewertz, M., and Wang, Y. (2014). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet, 383, 2127–2135.10.1016/S0140-6736(14)60488-8 ↗
6. World Health Organization, and International Agency for Research on Cancer (2024, August 22). Estimated Number of New Cases and Deaths from 2022 to 2045, Females, Age [0–85+] Breast. Available online: https://gco.iarc.fr/tomorrow/en/dataviz/isotype?sexes=2&single_unit=500000&cancers=20&years=2045.
7. Study of Failure Pattern Among High-Risk Breast Cancer Patients with or without Postmastectomy Radiotherapy in Addition to Adjuvant Systemic Therapy: Long-Term Results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c Randomized Studies10.1200/JCO.2005.02.8738 ↗
8. Prognostic factors of breast recurrence in the conservative management of early breast cancer: A 25-year follow-up10.1016/0360-3016(89)90057-6 ↗
9. Recurrence in the breast following conservative surgery and radiation therapy for early-stage breast cancer
10. Breast conservation: Predictors and treatment of local recurrence10.1002/(SICI)1098-2388(199609/10)12:5<332::AID-SSU8>3.0.CO;2-E ↗
11. Skin-Sparing Mastectomy and Immediate Breast Reconstruction in the Management of Locally Recurrent Breast Cancer10.1245/s10434-010-0957-8 ↗
12. Current Management for Late Normal Tissue Injury: Radiation-Induced Fibrosis and Necrosis10.1016/j.semradonc.2006.11.006 ↗
13. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial10.1200/JCO.2017.76.5719 ↗
14. European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: Definition, reporting, and clinical decision making10.1016/S1470-2045(22)00447-8 ↗
15. Oldenborg, S., Van Os, R., Oei, B., and Poortmans, P. (2019). Impact of Technique and Schedule of Reirradiation Plus Hyperthermia on Outcome after Surgery for Patients with Recurrent Breast Cancer. Cancers, 11.10.3390/cancers11060782 ↗
16. The results of radiation therapy for isolated local regional recurrence after mastectomy10.1016/0360-3016(91)90775-Y ↗
17. Repeat breast-conserving therapy for ipsilateral breast cancer recurrence: A systematic review10.1016/j.ejso.2019.02.008 ↗
18. Re-irradiation for locally recurrent refractory breast cancer10.18632/oncotarget.6036 ↗
19. Reirradiation for Locoregional Recurrent Breast Cancer10.1016/j.adro.2020.100640 ↗
20. Baude, J., Dendale, R., Cao, K., Fourquet, A., and Kirova, Y. (2023). Tolerance and Oncological Outcomes of In-Field Reirradiation for Locally Recurrent Breast Cancer: A Long-Term Single-Center Experience. Cancers, 15.10.3390/cancers15184515 ↗
21. 10-Year oncological outcome report after second conservative treatment for ipsilateral breast tumor event
22. Different Re-Irradiation Techniques after Breast-Conserving Surgery for Recurrent or New Primary Breast Cancer10.3390/curroncol30010088 ↗
23. Re-irradiation in clinical practice: Results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform10.1016/j.radonc.2023.109947 ↗
24. Can breast cancer be reirradiated?
25. DEGRO practical guidelines for radiotherapy of breast cancer VI: Therapy of locoregional breast cancer recurrences10.1007/s00066-015-0939-7 ↗